Cargando…

Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study

The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated. The aim of this study was to describe the characteristics of patients with fHP in a real-world cohort and investigate factors associated with worse outcomes. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Barratt, Shaney L, Creamer, Andrew W, Adamali, Huzaifa I, Duckworth, Anna, Fallon, Janet, Fidan, Silan, Nancarrow, Tom, Wollerton, Rebecca, Steward, Matthew, Gooptu, Bibek, Gibbons, Michael, Woodhead, Felix Alexander, Scotton, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603296/
https://www.ncbi.nlm.nih.gov/pubmed/34794958
http://dx.doi.org/10.1136/bmjresp-2021-001063
_version_ 1784601741540458496
author Barratt, Shaney L
Creamer, Andrew W
Adamali, Huzaifa I
Duckworth, Anna
Fallon, Janet
Fidan, Silan
Nancarrow, Tom
Wollerton, Rebecca
Steward, Matthew
Gooptu, Bibek
Gibbons, Michael
Woodhead, Felix Alexander
Scotton, Chris
author_facet Barratt, Shaney L
Creamer, Andrew W
Adamali, Huzaifa I
Duckworth, Anna
Fallon, Janet
Fidan, Silan
Nancarrow, Tom
Wollerton, Rebecca
Steward, Matthew
Gooptu, Bibek
Gibbons, Michael
Woodhead, Felix Alexander
Scotton, Chris
author_sort Barratt, Shaney L
collection PubMed
description The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated. The aim of this study was to describe the characteristics of patients with fHP in a real-world cohort and investigate factors associated with worse outcomes. We aimed to explore the use of neutrophil to lymphocyte ratio (NLR) and peripheral blood monocyte levels in predicting mortality. METHODS: A retrospective, multicentre, observational UK cohort study. RESULTS: Patients with fHP were significantly younger than those with idiopathic pulmonary fibrosis (IPF) (median age fHP 73 vs IPF 75 years) and were much more likely to be woman (fHP 61% vs IPF 26%). In almost half of all fHP cases (49%, n=104/211), no causative antigen was identified from either the history or specific antigen testing. Overall, fHP was associated with a better survival than IPF, although median survival of both groups was poor (fHP 62 months vs IPF 52 months). IPF survival in patients with a high NLR was significantly lower than those with a low NLR (44 vs 83 months). A monocyte count ≥0.95 K/uL also predicted significantly poorer outcomes for patients with IPF compared with <0.95 K/uL (33 vs 57 months). In contrast, NLR and monocyte count did not predict survival in the fHP cohort. CONCLUSIONS: Although fHP has a statistically lower mortality than IPF, absolute survival time of both conditions is poor. High baseline NLR and absolute monocyte counts predict worse survival in IPF but not in fHP, highlighting the potential for divergence in their pathogenic mechanisms.
format Online
Article
Text
id pubmed-8603296
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86032962021-12-03 Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study Barratt, Shaney L Creamer, Andrew W Adamali, Huzaifa I Duckworth, Anna Fallon, Janet Fidan, Silan Nancarrow, Tom Wollerton, Rebecca Steward, Matthew Gooptu, Bibek Gibbons, Michael Woodhead, Felix Alexander Scotton, Chris BMJ Open Respir Res Interstitial Lung Disease The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated. The aim of this study was to describe the characteristics of patients with fHP in a real-world cohort and investigate factors associated with worse outcomes. We aimed to explore the use of neutrophil to lymphocyte ratio (NLR) and peripheral blood monocyte levels in predicting mortality. METHODS: A retrospective, multicentre, observational UK cohort study. RESULTS: Patients with fHP were significantly younger than those with idiopathic pulmonary fibrosis (IPF) (median age fHP 73 vs IPF 75 years) and were much more likely to be woman (fHP 61% vs IPF 26%). In almost half of all fHP cases (49%, n=104/211), no causative antigen was identified from either the history or specific antigen testing. Overall, fHP was associated with a better survival than IPF, although median survival of both groups was poor (fHP 62 months vs IPF 52 months). IPF survival in patients with a high NLR was significantly lower than those with a low NLR (44 vs 83 months). A monocyte count ≥0.95 K/uL also predicted significantly poorer outcomes for patients with IPF compared with <0.95 K/uL (33 vs 57 months). In contrast, NLR and monocyte count did not predict survival in the fHP cohort. CONCLUSIONS: Although fHP has a statistically lower mortality than IPF, absolute survival time of both conditions is poor. High baseline NLR and absolute monocyte counts predict worse survival in IPF but not in fHP, highlighting the potential for divergence in their pathogenic mechanisms. BMJ Publishing Group 2021-11-18 /pmc/articles/PMC8603296/ /pubmed/34794958 http://dx.doi.org/10.1136/bmjresp-2021-001063 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Interstitial Lung Disease
Barratt, Shaney L
Creamer, Andrew W
Adamali, Huzaifa I
Duckworth, Anna
Fallon, Janet
Fidan, Silan
Nancarrow, Tom
Wollerton, Rebecca
Steward, Matthew
Gooptu, Bibek
Gibbons, Michael
Woodhead, Felix Alexander
Scotton, Chris
Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
title Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
title_full Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
title_fullStr Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
title_full_unstemmed Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
title_short Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
title_sort use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fhp): a multicentre retrospective cohort study
topic Interstitial Lung Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603296/
https://www.ncbi.nlm.nih.gov/pubmed/34794958
http://dx.doi.org/10.1136/bmjresp-2021-001063
work_keys_str_mv AT barrattshaneyl useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT creamerandreww useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT adamalihuzaifai useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT duckworthanna useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT fallonjanet useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT fidansilan useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT nancarrowtom useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT wollertonrebecca useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT stewardmatthew useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT gooptubibek useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT gibbonsmichael useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT woodheadfelixalexander useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy
AT scottonchris useofperipheralneutrophiltolymphocyteratioandperipheralmonocytelevelstopredictsurvivalinfibrotichypersensitivitypneumonitisfhpamulticentreretrospectivecohortstudy